by Francisca Peixoto | Jun 13, 2024 | Uncategorized
Our portfolio company Ochre Bio just announced a new, multi-year, data licence agreement with GSK. GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. This partnership will provide GSK with...
by Francisca Peixoto | May 7, 2024 | Uncategorized
A report by El País states that Spain stands as a benchmark in European drug clinical trials. Spain takes part in one out of every three tests that are launched in Europe, and comes second in the world – after the U.S. – in partaking in clinical trials. Back in 2021,...
by Francisca Peixoto | Apr 22, 2024 | Uncategorized
Our portfolio company Ochre Bio just signed a $1B partnership with Boehringer Ingelheim. Boehringer is a top 20 biopharmaceutical company by revenue and is the world’s largest private biopharma company, it is also a leader in liver disease R&D and has substantial...
by Francisca Peixoto | Apr 5, 2024 | Uncategorized
Our portfolio company InCephalo just appointed Dr. Lorenz Mayr as their new Chair. As the new Chairman of InCephalo, Dr. Lorenz Mayr brings his incredible experience in big names such as Bayer, Novartis, AstraZeneca, and Syncona. We, here at LifeLink Ventures, can’t...
by Francisca Peixoto | Apr 5, 2024 | Uncategorized
The CEO of our portfolio company Ochre Bio just did an interview with Judy Khan Shaw from the New York Stock Exchange. As published by NYSE on LinkedIn here: “Ochre Bio is on a mission to revolutionize liver disease treatment. Co-Founder + CEO Jack O’Meara...
